您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Isatuximab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Isatuximab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1461640-62-9
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
Isatuximab 是一种单克隆抗体,靶向跨膜受体和胞外酶 CD38,一种在血液系统恶性细胞,包括多发性骨髓瘤中高度表达的蛋白。Isatuximab 通过多种生物学机制具有抗肿瘤活性,包括抗体依赖性细胞介导的细胞毒性、补体依赖性细胞毒性、抗体依赖性细胞吞噬作用和无交联直接诱导细胞凋亡 (apoptosis)。Isatuximab 还直接抑制 CD38 胞外酶活性,这与许多细胞功能有关。
Cas No.1461640-62-9
别名艾萨妥昔单抗
储存条件Store at 4℃, do not freeze
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions[1][2].

An in-vitro study shows that the combination of Isatuximab with Pomalidomide (an immunomodulatory drug) results in greater direct toxicity and lysis of CD38 multiple myeloma cells by effector cells compared with Isatuximab alone[2].

[1]. Dhillon S. Isatuximab: First Approval [published correction appears in Drugs. 2020 May 23;:]. Drugs. 2020;80(9):905-912.
[2]. Attal M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [published correction appears in Lancet. 2019 Dec 7;394(10214):2072]. Lancet. 2019;394(10214):2096-2107.